IBIO iBio, Inc.: Forward P/S Multiple
iBio, Inc. (IBIO) is currently in the pre-revenue research phase, meaning its market capitalization relies on future contracts. The application of AI to develop oncology antibodies ensures long-term patent protection and royalties. The business's forward P/S confirms market expectations, with the value stabilizing at 45.10. The company's success depends on test results and the willingness of pharma behemoths to license the developed vaccines.
IBIO (iBio Corporation): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
IBIO - Net Income|Future Profit iBio, Inc.|IBIO - Business Payback Period|Forward P/E Multiple iBio Corp|IBIO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple iBio Corporation|IBIO - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) iBio|IBIO - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months ibioinc.com|IBIO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year iBio, Inc.
- sales revenue and business income indicators:
Summary company analysis:iBio IBIO
This indicator compares the current market value of iBio, Inc. (IBIO) with projected sales volumes, allowing for an assessment of whether the asset is overvalued or undervalued relative to future cash flows. By analyzing the forward P/S based on forecasts, an investor can determine the extent to which the market has priced in future royalties from AI-driven molecule discovery and licensing revenues from antibodies within the immuno-oncology segment.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|PTGX: Forward P/S Multiple|IMVT (immunovant.com) - Price-to-Projected Revenue Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX - Market Cap to Future Revenue Ratio|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales BCRX|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ABCL|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple precigen.com (PGEN)|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Forward P/S Multiple UPB (Upstream Bio Corp)|Market Cap to Expected Sales Ratio Zenas Corp (ZBIO)|Immunome, Inc. - Forward P/S Multiple|GOSS: Price-to-Projected Revenue Ratio|KALV: Forward P/S Multiple|SEPN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Market Cap to Future Revenue Ratio Savara Pharma SVRA|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|ANAB: Future Price to Revenue|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Forward Price to Sales ENGN|RAPT Therapeutics, Inc. - Forward P/S Multiple|JBIO - Forward P/S Multiple|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|kyvernatx.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Avalo Therapeutics, Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales ELDN|Agenus Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Climb Bio Inc. CLYM|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple aTyr Pharmaceuticals|Price-to-Projected Revenue Ratio Adagene Inc|Forward Price-to-Revenue Multiple Ikena Oncology, Inc. (IMA)|Forward Price-to-Revenue Multiple STTK (Shattuck Labs, Inc.)|Forward P/S Multiple equilliumbio.com (EQ)|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX: Market Cap to Projected Revenue|Atara Biotherapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio InflaRx N.V.|XFOR: Forward P/S Multiple|ACET - Market Cap to Expected Sales Ratio|CELU (Celularity Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INMB|Forward P/S Multiple BRNS|Market Cap to Expected Sales Ratio kezarlifesciences.com|Price-to-Projected Revenue Ratio SAB Biotherapeutics, Inc. SABS|Akari Therapeutics PLC (AKTX) - Market Cap to Future Revenue Ratio|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (Q32 Bio Inc.)|GOVX: Forward P/S Multiple|EDSA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Forward P/S Multiple BOLT|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio AIM ImmunoTech, Inc. (AIM)|Aditxt Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XRTX: Forward P/S Multiple|HIND (Vyome Therapeutics) - Price-to-Projected Revenue Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK (Allakos Inc) - Future Price to Revenue|HOOKIPA - Forward P/S Multiple|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD: Forward Price to Sales
